CoreVision Biopharma Closes Nearly RMB 100 Million Angel Round, Pioneering Visualized Theranostic Targeted Radiopharmaceuticals
Dedicated to becoming a trailblazer in China's TRT space.
Jinghe Biopharmaceutical Technology (Nanjing) Co., Ltd. ("Jinghe Bio") announced the completion of an angel round of nearly RMB 100 million, led by Gaorong Ventures, with participation from VI Ventures, Lichen Capital, and existing shareholder Kaitai Capital.
The proceeds will primarily accelerate the clinical advancement of multiple innovative targeted radiopharmaceuticals in Jinghe Bio's pipeline and upgrade its radiopharmaceutical R&D platform to further solidify its leading position in the targeted radiopharmaceutical field.
Veteran Team Focused on Targeted Radiopharmaceutical Development
Jinghe Bio is a biopharmaceutical company dedicated to developing targeted radiotheranostics (TRT), with three technology platforms covering targeted ligand screening, radiopharmaceutical conjugation, and clinical translation — all aimed at benefiting cancer patients and those with other serious diseases worldwide.
Founded in 2021 by Dr. Haihua Yu, Dr. Yu Wang, and two other co-founders, Jinghe Bio brings together deep industry experience. Dr. Haihua Yu previously spent over a decade in new drug R&D at GSK before joining Huayi Technology to lead its Molecular Imaging and Drug Research Institute. Dr. Yu Wang spent more than 20 years at internationally renowned pharmaceutical companies including Endocyte (acquired by Novartis) and Eli Lilly, working on small-molecule radiopharmaceuticals and various targeted conjugate drugs, with experience bringing multiple candidates through US NDA/IND filings.
Aiming to Pioneer China's TRT Field and Deliver Novel Therapeutic Options
"This new round of investment from leading VCs like Gaorong Ventures and VI Ventures, along with the continued trust and support from our existing shareholders, represents not only recognition of the Jinghe Bio team and our programs, but also reflects the industry's optimism toward theranostic targeted radiopharmaceuticals," said Dr. Haihua Yu, co-founder of Jinghe Bio.
Dr. Yu explained that theranostic targeted radiopharmaceuticals enable whole-body dynamic, non-invasive early visualization for diagnosis and staging via PET/CT and other imaging modalities, while also allowing treatment response assessment. Meanwhile, targeted radiotherapy drugs (TRT) combine the precision of targeted agents with the power of physical radiation, addressing current clinical pain points around dosing, safety, and drug resistance — offering patients at home and abroad entirely new therapeutic options.
A Gaorong Ventures representative commented: "Targeted radiopharmaceuticals represent a novel, differentiated therapeutic modality with tremendous global market potential. Compared to traditional drugs, their development approach and screening evaluation differ significantly, presenting greater challenges and higher technical barriers. Jinghe Bio's founding team hails from industry-leading companies including Endocyte/Novartis, Siemens, GSK, and Huayi Technology, with experience developing internationally approved radiopharmaceuticals. We believe the team will leverage its platform strengths to accelerate pipeline development and bring new hope to patients worldwide."
About Jinghe Bio
Established in 2021, Jinghe Bio's co-founding team brings together talent from Endocyte/Novartis, Siemens, Lilly, Roche, GSK, and other major international pharmaceutical companies, with extensive experience in innovative radiopharmaceutical development. The company is committed to leading and advancing China's innovative radiopharmaceutical sector, guided by a patient-centric philosophy and a pursuit of excellence ("jing" 晶). Drawing on its collective expertise and technology platforms, Jinghe Bio strives to bring safer and more effective innovative medicines to patients globally.
